دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
3-Year Outcomes After Transcatheter or Surgical Aortic Valve Replacement in Low-Risk Patients With Aortic Stenosis
John K. Forrest, MD,a G. Michael Deeb, MD, b Steven J. Yakubov, MD, c Hemal Gada, MD,d Mubashir A. Mumtaz, MD, d Basel Ramlawi, MD, e Tanvir Bajwa, MD,f Paul S. Teirstein, MD, g Michael DeFrain, MD,h Murali Muppala, MD, h Bruce J. Rutkin, MD, i Atul Chawla, MD, j Bart Jenson, MD, j Stanley J. Chetcuti, MD, b Robert C. Stoler, MD, k Marie-France Poulin, MD, l Kamal Khabbaz, MD,l Melissa Levack, MD,m Kashish Goel, MD, m Didier Tchétché, MD, n Ka Yan Lam, MD, o Pim A.L. Tonino, MD,o Saki Ito, MD,p Jae K. Oh, MD,p Jian Huang, MD, MS C,q Jeffrey J. Popma, MD, q Neal Kleiman, MD, r Michael J. Reardon, MD, r on behalf of the Low Risk Trial Investigators
doi : 10.1016/j.jacc.2023.02.017
Volume 81, Issue 17, 2 May 2023, Pages 1663-1674
Randomized data comparing outcomes of transcatheter aortic valve replacement (TAVR) with surgery in low–surgical risk patients at time points beyond 2 years is limited. This presents an unknown for physicians striving to educate patients as part of a shared decision-making process.
Transcatheter vs Surgical Aortic Valve Replacement in Low-Risk Patients: So Far (3 Years), So Good∗
Philippe Pibarot, DVM, P HD
doi : 10.1016/j.jacc.2023.03.006
Volume 81, Issue 17, 2 May 2023, Pages 1675-1679
Virtual Care Team Guided Management of Patients With Heart Failure During Hospitalization
Ankeet S. Bhatt, MD, MBA, SCM, a,b, * Anubodh S. Varshney, MD,c, * Alea Moscone, MPH,d Brian L. Claggett, PHD, a Zi Michael Miao, MS, a Safia Chatur, MD, a Mathew S. Lopes, MD, MPH, a John W. Ostrominski, MD, a Maria A. Pabon, MD,a Ozan Unlu, MD, a Xiaowen Wang, MD, a Thomas D. Bernier, PHARMD, e Leo F. Buckley, P HARMD, f Bryan Cook, PHARMD, g Rachael Eaton, P HARMD, MBA, h Jillian Fiene, PHARM D, f Dareen Kanaan, P HARMD, MPH,f Julie Kelly, PHARMD, i Danielle M. Knowles, PHARMD, f Kenneth Lupi, PHARMD, f Lina S. Matta, PHARMD, MPH,f Liriany Y. Pimentel, PHARMD, f Megan N. Rhoten, PHARMD, j Rhynn Malloy, PHARMD, k Clara Ting, P HARMD, l Rosette Chhor, PHARMD, m Joshua R. Guerin, PHARMD, MBA, m Scott L. Schissel, MD, P HD, m Brenda Hoa, PHARMD, m Connie H. Lio, PHARMD, m Kristina Milewski, P HARMD, m Michelle E. Espinosa, PHARMD, m Zhenzhen Liu, PHARMD, n Ralph McHatton, P HARMD, n Jonathan W. Cunningham, MD,a Karola S. Jering, MD, a John H. Bertot, MD,d Gurleen Kaur, MD,d Adeel Ahmad, MD,n Muhammad Akash, MD,n Farideh Davoudi, MD, n Mona Z. Hinrichsen, MD,n David L. Rabin, MD,n Patrick L. Gordan, MD, MBA, n David J. Roberts, MD, n Daniela Urma, MD,n Erin E. McElrath, MBA, d Emily D. Hinchey, MBA, d Niteesh K. Choudhry, MD, P HD, d Mahan Nekoui, MD,o Scott D. Solomon, MD,a Dale S. Adler, MD,a,d Muthiah Vaduganathan, MD, MPH
doi : 10.1016/j.jacc.2023.02.029
Volume 81, Issue 17, 2 May 2023, Pages 1680-1693
Scalable and safe approaches for heart failure guideline-directed medical therapy (GDMT) optimization are needed.
Team-Based Virtual Nudges to Overcome Clinician Inertia in Guideline-Directed Medical Therapy for Heart Failure∗
Gregg C. Fonarow, MD, a Harriette G.C. Van Spall, MD, MPH,b James L. Januzzi, J R, MD
doi : 10.1016/j.jacc.2023.02.047
Volume 81, Issue 17, 2 May 2023, Pages 1694-1696
Health Status and Clinical Outcomes in Older Adults With Chronic Coronary Disease: The ISCHEMIA Trial
Dan D. Nguyen, MD, a,b John A. Spertus, MD, MPH, a,b Karen P. Alexander, MD, c Jonathan D. Newman, MD, MPH, d John A. Dodson, MD, MPH,d Philip G. Jones, MS,a,b Susanna R. Stevens, MS, c Sean M. O’Brien, P HD, c Reto Gamma, MBBS, e Gian P. Perna, MD,f Pallav Garg, MBBS, MSC ,g Jo?o V. Vitola, MD, PH D, h Benjamin J.W. Chow, MD,i Andras Vertes, MD,j Harvey D. White, MB CH B, DS C ,k,l Paola E.P. Smanio, MD, PH D, m Roxy Senior, MD, DM,n Claes Held, MD, P HD, o,p Jianghao Li, PHD, c William E. Boden, MD,q Daniel B. Mark, MD, MPH, c Harmony R. Reynolds, MD,d Sripal Bangalore, MD, MHA, d Paul S. Chan, MD, MS C,a,b Gregg W. Stone, MD, r,s Suzanne V. Arnold, MD, MHA, a,b David J. Maron, MD, t Judith S. Hochman, MD, d on behalf of the ISCHEMIA Research Group
doi : 10.1016/j.jacc.2023.02.048
Volume 81, Issue 17, 2 May 2023, Pages 1697-1709
Whether initial invasive management in older vs younger adults with chronic coronary disease and moderate or severe ischemia improves health status or clinical outcomes is unknown.
Stable Coronary Artery Disease in the Age of Geriatric Cardiology∗
Parag Goyal, MD, MS C, a Michael G. Nanna, MD, MHS
doi : 10.1016/j.jacc.2023.03.378
Volume 81, Issue 17, 2 May 2023, Pages 1710-1713
Low Utilization of Lead Extraction Among Patients With Infective Endocarditis and Implanted Cardiac Electronic Devices
Christopher T. Sciria, MD, a,b Edward V. Kogan, MD,a Ari G. Mandler, MD,a Ilhwan Yeo, MD, PH D, a Matthew S. Simon, MD, c Luke K. Kim, MD, a James E. Ip, MD, a Christopher F. Liu, MD, a Steven M. Markowitz, MD, a Bruce B. Lerman, MD,a George Thomas, MD,a Jim W. Cheung, MD
doi : 10.1016/j.jacc.2023.02.042
Volume 81, Issue 17, 2 May 2023, Pages 1714-1725
Cardiac implantable electronic device (CIED)-associated infections are associated with substantial morbidity, mortality, and costs. Guidelines have cited endocarditis as a Class I indication for transvenous lead removal/extraction (TLE) among patients with CIEDs.
Cardiac Implantable Electronic Devices and Infective Endocarditis: A Call to Arms…∗
Ayman A. Hussein, MD, Oussama M. Wazni, MD, Bruce L. Wilkoff, MD
doi : 10.1016/j.jacc.2023.02.043
Volume 81, Issue 17, 2 May 2023, Pages 1726-1728
Gut Microbiome-Based Management of Patients With Heart Failure: JACC Review Topic of the Week
Petra Mamic, MD, a,b Michael Snyder, PH D, b W.H. Wilson Tang, MD
doi : 10.1016/j.jacc.2023.02.045
Volume 81, Issue 17, 2 May 2023, Pages 1729-1739
Despite therapeutic advances, chronic heart failure (HF) is still associated with significant risk of morbidity and mortality. The course of disease and responses to therapies vary widely among individuals with HF, highlighting the need for precision medicine approaches.
ACC: Gaining Momentum and Changing the World
B. Hadley Wilson, MD, FACC, President, American College of Cardiology
doi : 10.1016/j.jacc.2023.03.397
Volume 81, Issue 17, 2 May 2023, Pages 1740-1742
CDC-WONDER Database Analysis of COVID-19 and Cardiovascular Disease-Related Mortality
Muhammad Haisum Maqsood, MD Khawaja M. Talha, MD Abdul Mannan Khan Minhas, MD Marat Fudim, MD, MHS Sadiya S. Khan, MD, MSc Javed Butler, MD, MPH, MBA *Muhammad Shahzeb Khan, MD, MSc
doi : 10.1016/j.jacc.2023.02.044
Volume 81, Issue 17, 2 May 2023, Pages 1743-1745
The Nuance of Studying and Prescribing Supplements
Julita Mitchell, MD Eugene Storozynsky, MD, PhD Ana Maria Lopez, MD, MPH
doi : 10.1016/j.jacc.2023.01.048
Volume 81, Issue 17, 2 May 2023, Page e149
Reply: The Nuance of Studying and Prescribing Supplements
Luke J. Laffin, MD *Steven E. Nissen, MD
doi : 10.1016/j.jacc.2023.02.046
Volume 81, Issue 17, 2 May 2023, Page e151
